Association of Warfarin Therapy With Apoe and Vkorc1 Genes Polymorphism in Iranian Population



Rafiee S¹ ; Rajabibazl M^{1, 2} ; Meshkani R³ ; Daraei A¹ ; Zargari M⁴ ; Sharafeddin F⁴ ; Fazeli Z⁵ ; Milani AT¹ ; Taherkhani M⁶ Show Affiliations
Source: Iranian Journal of Pharmaceutical Research Published:2017

Abstract

Warfarin is a vitamin K antagonist that genetic and non-genetic factors affected on its dose requirement in the patients with cardio vascular disease. The aim of this study was whether the APOE and VKORC1 polymorphisms influence on warfarin dose requirements in the part of Iranian patients. Blood samples were collected from 86 warfarin-treated patients. After extraction of genomic DNA, the VKORC1 (rs9923231) and the APOE (rs429358 and rs7412) polymorphisms were genotyped by PCR-RFLP technique. We found that the Iranian patients carrying genotypes GA or AA of VKORC1 polymorphism tended to receive lower dose of warfarin (p = 0.018). Furthermore, the E3/E3 genotype was observed with the frequency more than 60% in the patients with low dose of warfarin. The BMI and weight also showed a positive correlation with warfarin dose. However, it was not statistically significant (p > 0.05). The results of this study may be useful in defining of warfarin dose algorithms for Iranian patients. © 2017 by School of Pharmacy Shaheed Beheshti University of Medical Sciences and Health Services.